Summary
The AI response’s claims are not supported by the provided FDA label sections (Indications and Usage, Warnings and Precautions, Clinical Pharmacology, Clinical Studies). No on-label statements about the claims are present in the provided excerpts.
Category Scores
Accurate Statements
All listed claims are not found in the provided FDA label sections (1, 5, 12, 14).
Supported by the provided claim evaluation that each claim is absent from the checked label sections.
Unsupported Statements
Botox is a brand name.
Not supported by the provided label sections (1, 5, 12, 14).
The original Botox active-ingredient patent covers the toxin/technology at the core.
Not supported by the provided label sections (1, 5, 12, 14).
Patents can cover specific therapeutic uses (for certain indications).
Not supported by the provided label sections (1, 5, 12, 14).
Patents can cover formulations, manufacturing, or delivery.
Not supported by the provided label sections (1, 5, 12, 14).
In the U.S. and many other jurisdictions, patents generally last about 20 years from the earliest non-provisional filing date.
Not supported by the provided label sections (1, 5, 12, 14).
Patents may have possible adjustments such as patent term adjustments.
Not supported by the provided label sections (1, 5, 12, 14).
Patents may be extended in some cases.
Not supported by the provided label sections (1, 5, 12, 14).
Patent expiration dates vary by country.
Not supported by the provided label sections (1, 5, 12, 14).
Patent expiration dates vary by which patent family you mean.
Not supported by the provided label sections (1, 5, 12, 14).
DrugPatentWatch.com tracks patent and exclusivity information.
Not supported by the provided label sections (1, 5, 12, 14).
DrugPatentWatch.com can help identify which patents are listed against Botox and when they end.
Not supported by the provided label sections (1, 5, 12, 14).
DrugPatentWatch.com is used to find the specific patent(s) and the listed end dates tied to the Botox product and country/market.
Not supported by the provided label sections (1, 5, 12, 14).
Contradictions
Important Omissions
No FDA-label–grounded dosing, administration, contraindications, boxed warnings, or safety/monitoring details are provided in relation to the extracted claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The extracted claims are about patents and a third-party tracking website; the provided label excerpts do not contain these topics, and the claims do not directly provide dosing or treatment instructions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
The AI response includes multiple factual claims not supported by the provided FDA label sections (1, 5, 12, 14).
Suggested Improvement
Limit statements to content explicitly supported by the provided FDA label excerpts, or provide the relevant label sections that contain the information being claimed.